世界のリソソーム酸性リパーゼ欠損症（LAL-D）市場 - 2030 年までの業界動向と予測

リソソーム酸性リパーゼ欠損症（LAL-D）市場分析と規模

リソソーム酸性リパーゼ欠損症（LAL-D）は、ウォルマン病またはコレステロールエステル蓄積症（CESD）としても知られ、リソソーム酸性リパーゼ酵素の欠損を特徴とする希少な遺伝性疾患です。この酵素は、体内で脂肪やコレステロールを分解する上で重要な役割を果たします。この酵素が欠損または機能しない場合は、さまざまな組織や臓器に脂質（脂肪）が蓄積し、さまざまな症状や健康上の合併症を引き起こします。診断ツールと遺伝子検査の進歩により、LAL-Dの症例を特定して確認することが容易になりました。この疾患を効果的に管理するには、早期かつ正確な診断が不可欠です。長年にわたり、医療従事者、患者、一般の人々の間で、LAL-Dなどの希少疾患に関する認識が大幅に高まっています。この認識の高まりにより、この疾患のより正確な診断と治療が実現しています。

データブリッジ市場調査は、2022年に6億1,200万米ドルであった（LAL-D）市場は、2030年までに13億1,188万米ドルに達すると予想され、予測期間中に10.0％のCAGRを達成すると予測しています。これは、市場価値を示しています。 「早期発症ウォルマン病」は、後期段階の失敗と治療セグメントの開発に役立つ前臨床スクリーニング活動に投資する製薬会社とバイオ製薬会社の増加により、リソソーム酸性リパーゼ欠損症（LAL-D）市場のタイプセグメントを支配しています。市場価値、成長率、セグメンテーション、地理的範囲、主要プレーヤーなどの市場シナリオに関する洞察に加えて、データブリッジ市場調査によってまとめられた市場レポートには、詳細な専門家の分析、患者の疫学、パイプライン分析、価格設定分析、規制の枠組みも含まれています。

リソソーム酸性リパーゼ欠損症（LAL-D）市場の範囲とセグメンテーション

Market Definition

Lysosomal acid lipase deficiency (LAL-D) market is the commercial and healthcare ecosystem related to the diagnosis, treatment, and management of lysosomal acid lipase deficiency, also known as wolman disease or cholesteryl ester storage disease (CESD). LAL-D is a rare genetic disorder characterized by a deficiency of the lysosomal acid lipase enzyme, which plays a crucial role in breaking down fats and cholesterol in the body. When this enzyme is deficient or nonfunctional, it leads to the accumulation of lipids (fats) in various tissues and organs, causing a wide range of symptoms and health complications.

Global Lysosomal Acid Lipase Deficiency (LAL-D) Market Dynamics

Drivers

• Advancements in Diagnostic Technologies

Advances in diagnostic tools and genetic testing have made it easier to diagnose LAL-D. More accurate and accessible diagnostic methods enable earlier identification of affected individuals, which is crucial for timely intervention.

• Patient Advocacy and Support

Patient advocacy groups and foundations dedicated to LAL-D raise awareness, provide support to affected individuals and their families, and actively promote research. Their efforts help drive interest and investment in finding effective treatments.

Opportunity

• Evolving Healthcare Landscape

Changes in healthcare systems, such as an increased focus on rare diseases, personalized medicine, and precision diagnostics, contribute to the growth of the LAL-D market. Healthcare providers are better equipped to diagnose and manage rare diseases such as LAL-D.

Moreover, the demand for lysosomal acid lipase deficiency (LAL-D) is not only limited to developed countries but is also being witnessed in the developing countries which will further act as driver that will lead to the growth of the lysosomal acid lipase deficiency (LAL-D) market in the above mentioned projected timeframe.

Restraint/Challenge

• Long Development Timelines

Developing treatments for rare diseases often involves lengthy research and development timelines, including clinical trial phases. This can delay the availability of therapies for patients who urgently need them.

Recent Developments

• Currently, Alexion Pharma’s Kanuma is the only product approved for LAL-D treatment. Kanuma (sebelipase alfa) is a subcutaneously delivered enzyme replacement treatment(ERT) approved in the EU (September 2015), U.S. (December 2015), and Japan (March 2016) for LAL-D patients
• In addition, the CESD cohort is prescribed statins and other nutritional supplements. Pfizer (Lipitor) and Merck (Zetia) are key players in the statins segment of the CSED market. However, these companies are poised to lose market share on account of significant competition from generics and approval of ERT for both early and late-onset types of this disease.  Unmet needs within the LAL-D space present a strong opportunity to develop novel first-in-class therapies

Global Lysosomal Acid Lipase Deficiency (LAL-D) Market Scope

The lysosomal acid lipase deficiency (LAL-D) market is segmented on the basis of type, treatment, route of administration, end-users, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Early Onset Wolman Disease
• Late onset CESD

Treatment

• Enzyme Replacement Therapy
• Lipid-Modifying Agents (Statins)
• Surgery
• Stem Cell Transplantation
• Supportive Care

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Clinics
• Hospitals
• Ambulatory Surgical Centre
• Others

Distribution Channel

• Direct Tender
• Retail Pharmacy
• Hospital Pharmacy
• Others

Global Lysosomal Acid Lipase Deficiency (LAL-D) Market Regional Analysis/Insights

The lysosomal acid lipase deficiency (LAL-D) market is analysed and market size insights and trends are provided by type, treatment, route of administration, end-users, and distribution channel as mentioned above.

The countries covered in the lysosomal acid lipase deficiency (LAL-D) market report are U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E., Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa

North America is expected to dominate the lysosomal acid lipase deficiency (LAL-D) market due to rise in the presence of key players and increased funding from public and private entities have augmented drug discovery and development and rise in the volume of expenditure carried out for advancing the technologies available for development of pharmaceuticals in this region.

Asia-Pacific is expected to grow at the highest growth rate during the forecast period of 2023 to 2030 due to rise in the availability of numerous advanced technologies utilized for protein binding in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and up-stream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The lysosomal acid lipase deficiency (LAL-D) market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for lysosomal acid lipase deficiency (LAL-D) market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the lysosomal acid lipase deficiency (LAL-D) market. The data is available for historic period 2015 to 2020.

Competitive Landscape and Lysosomal Acid Lipase Deficiency (LAL-D) market Share Analysis

リソソーム酸性リパーゼ欠損症 (LAL-D) 市場の競争状況は、競合他社ごとに詳細を提供します。詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、世界的なプレゼンス、生産拠点と施設、生産能力、会社の強みと弱み、製品の発売、製品の幅と広さ、アプリケーションの優位性が含まれます。提供されている上記のデータ ポイントは、リソソーム酸性リパーゼ欠損症 (LAL-D) 市場に関連する会社の焦点にのみ関連しています。

リソソーム酸性リパーゼ欠損症 (LAL-D) 市場で活動している主要企業は次のとおりです。

• アレクシオンファーマシューティカルズ社（米国）
• ファイザー社（米国）
• モレペン（インド）
• ルパン（インド）
• トリヴェニ・インターケム・プライベート・リミテッド（インド）
• ラネット（米国）
• ヘテロヘルスケアリミテッド（インド）
• サン・ファーマシューティカル・インダストリーズ（インド）
• ジダス・カディラ（インド）
• サンドス・インターナショナル GmbH (ドイツ)
• バイオクリックバイオテック（中国）
• アクティザ製薬株式会社（インド）
• テバファーマシューティカルズUSA社（米国）
• グレンマーク製薬株式会社（インド）
• ANGLE BIO PHARMA（インド）
• アコードヘルスケアリミテッド（インド）
• アストラゼネカ（英国）
• プルデンス・ファーマ・ケム（インド）
• ノバドス・ファーマシューティカルズ（米国）
• Merck Sharp & Dohme Corp.（米国Merck & Co., Inc.の子会社）
• ペリゴ カンパニー plc (アイルランド)

SKU-60215